Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
Sep 27, 2021, 07:30 ET CRANBURY, N.J., Sept. 27, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the presentation of the protective effects of melanocortin 1 receptor agonists PL8331 and PL9654 in mouse models […]